Pioneering mRNA Therapies for Lung Diseases

Xtalks Life Science Podcast

Контент предоставлен Xtalks. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией Xtalks или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.

6M ago 34:15

MP4•Главная эпизода

In this episode, Vera spoke with Carsten Rudolph, PhD, CEO of Ethris.

Ethris was founded by Dr. Rudolph and Professor Christian Plank with the goal of establishing messenger RNA (mRNA) as a novel drug modality for lung diseases such as asthma and rare pulmonary conditions like primary ciliary dyskinesia (PCD) and pulmonary alveolar proteinosis.

Ethris leverages its proprietary SNIM® RNA platform and lipidoid nanoparticle (LNP) delivery technology for versatile, multi-route therapeutic applications.

As mRNA therapies gain global traction, Dr. Rudolph sees opportunities for Ethris to make an impact.

Tune into the episode to explore the promise of nasal delivery of mRNA therapeutics as an innovative approach to treating lung diseases like asthma and beyond.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/
Follow Us on Social Media

Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured

200 эпизодов

#Science #Biology #Xtalks #Pharma #Biotech #Biotechnology #Medical Device #Drug Safety #Pharmaceutical Manufacturing #Clinical Research #Clinical Trials #Drug Development #Laboratory #Podcasting Education #Video #Pharmaceutical #Life Sciences